

Demographic Information:

| | | | |
|---------------------------------|--|---------------------------------|-----------------------|
| Patient Name _____ | | Date of Birth _____ | |
| Home Address _____ | | | |
| City, State, Zip _____ | | | |
| Home Phone _____ | | Mobile or Work Phone _____ | |
| Primary Insurance Name _____ | | | |
| Primary Insurance ID _____ | | Primary Insurance Group _____ | |
| Insured Name _____ | | Insured Date of Birth _____ | |
| Secondary Insurance Name _____ | | Insurance ID _____ | Insurance Group _____ |
| Secondary Insurance ID _____ | | Secondary Insurance Group _____ | |
| Ordering Physician's Name _____ | | | |
| Address _____ | | | |
| City, State, Zip _____ | | | |
| Phone _____ | | Fax _____ | |
| NPI _____ | | | |

Please fax the following information:

- History and Physical Pertinent Lab Work
- Front & Back copy(s) of patient's insurance card(s)

I authorize KabaFusion and its representatives to act as an agent and initiate and execute any insurance prior authorization process for this prescription, and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to KabaFusion.

Physician Signature: _____

Date: _____

Prescription:

Intravenous Immunoglobulin

- 0.4 gm/kg 1gm/kg 2gm/kg _____ grams

Infuse: IV daily x _____ day(s); repeat every _____ week(s) x _____ cycles

Other: _____

Hydration order: _____mls NS iv to be infused prior/post IVIG.

- Pre-medications: Acetaminophen 650mg PO 30 mins prior to infusion Other Pre-medications: _____
 Diphenhydramine 25mg PO 30 mins prior to infusion

Subcutaneous Immunoglobulin

Infuse _____ grams OR _____ mls

using _____ sites _____ time(s) per week

for _____ months.

Clinical Information:

Patient Weight: _____ Height: _____ Allergies: _____

- IV access [for IVIg patients only]: _____ Nurse to place PIV prior to therapy

| Diagnosis | ICD-10 | Diagnosis | ICD-10 |
|---|--------|--|--------|
| Neuromuscular: | | Immune Deficiency: | |
| <input type="checkbox"/> Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | G61.81 | <input type="checkbox"/> CVID w/ Predominant Immunoregulatory T-Cell Disorders | D83.1 |
| <input type="checkbox"/> Dermatopolymyositis | M33.90 | <input type="checkbox"/> Combined Immunodeficiency, Unspecified | D81.9 |
| <input type="checkbox"/> Guillain-Barre Syndrome (GBS) | G61.0 | <input type="checkbox"/> Common Variable Immunodeficiency, Unspecified | D83.9 |
| <input type="checkbox"/> Multifocal Motor Neuropathy | G61.82 | <input type="checkbox"/> Hereditary Hypogammaglobulinemia | D80.0 |
| <input type="checkbox"/> Myasthenia Gravis (MG) | G70.0 | <input type="checkbox"/> Immunodeficiency with Increased IgM | D80.5 |
| <input type="checkbox"/> Myasthenia Gravis with (Acute) Exacerbation | G70.01 | <input type="checkbox"/> Nonfamilial Hypogammaglobulinemia | D80.1 |
| <input type="checkbox"/> Polymyositis | M33.20 | <input type="checkbox"/> Other combined Immunodeficiencies | D81.89 |
| <input type="checkbox"/> Relapsing Remitting Multiple Sclerosis (RRMS) | G35 | <input type="checkbox"/> Other Common Variable Immunodeficiencies | D83.9 |
| <input type="checkbox"/> Stiff Person Syndrome | G25.82 | <input type="checkbox"/> Pemphigoid | L12.0 |
| Other: | | <input type="checkbox"/> Pemphigus | L10.9 |
| <input type="checkbox"/> Autoimmune Encephalopathy | G04.81 | <input type="checkbox"/> SCID with Low or Normal B-Cell Numbers | D81.2 |
| <input type="checkbox"/> Idiopathic Thrombocytopenic Purpura | D69.3 | <input type="checkbox"/> SCID with Low T- and B- Cell Numbers | D81.1 |
| <input type="checkbox"/> Inflammatory Neuropathies | G61.89 | <input type="checkbox"/> Selective deficiency of IgG Subclasses | D80.3 |
| | | <input type="checkbox"/> Specific Antibody Deficiency | D80.6 |
| | | <input type="checkbox"/> Systemic lupus erythematosus (SLE) | M32.9 |

Please Draw:

- CBC/diff CMP IgG w/subclasses 1-4 Quant. Ig
 _____ _____ Frequency: _____

PER Anaphylaxis Protocol:

- Adult – EpiPen 0.3 auto-injector dual pack
 Pediatric – EpiPen 0.15 auto-injector dual pack
 * Administer intramuscularly in the event of ADR*
 [May repeat x 1. **Order is valid for 1 year**]. **Use generic if applicable**

Notes:

If applicable, flush intravenous access device per KabaFusion protocol:

| Access | NS | Heparin |
|-----------------------------------|---|---|
| Peripheral | 1-3ml before/after use | 10u/ml 1-2mls after last NS flush |
| Midline, central (non-port), PICC | NS 5-10 mls before/after use; 10mls after blood draw | 10 u/ml 3-5mls after last NS flush; 5mls after blood draw |
| Implanted Port | 5-10mls before/after use; 20mls after blood draw | 100 u/ml 5mls after last NS flush; 5mls after blood draw |
| Tunneled | 5-10mls before/after use; 20mls after blood draw | 10 u/ml 3- mls after last NS flush. 5mls after blood draw |
| Groshong PICC, Midline | 5-10mls before/after use; 10mls after blood draw | NO Heparin needed |